Northwestern Mutual Wealth Management Co. Has $3.52 Million Stock Position in GSK PLC Sponsored ADR $GSK

Key Points

• Northwestern Mutual Wealth Management Co. increased its stake in GSK PLC by 15.8% during Q1, now holding 90,854 shares valued at approximately $3.52 million.
• GSK recently reported better-than-expected earnings of $1.23 EPS with revenues of $10.64 billion, exceeding analyst estimates.
• The company has declared a quarterly dividend of $0.4206, reflecting an annualized dividend yield of 4.3%, with an upcoming payment date of October 9.

Northwestern Mutual Wealth Management Co. boosted its stake in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 15.8% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 90,854 shares of the pharmaceutical company's stock after buying an additional 12,408 shares during the period. Northwestern Mutual Wealth Management Co.'s holdings in GSK were worth $3,520,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of GSK. HHM Wealth Advisors LLC boosted its position in shares of GSK by 222.2% during the 1st quarter. HHM Wealth Advisors LLC now owns 667 shares of the pharmaceutical company's stock valued at $26,000 after purchasing an additional 460 shares in the last quarter. Costello Asset Management INC bought a new position in shares of GSK during the 1st quarter valued at about $31,000. Richardson Financial Services Inc. boosted its position in shares of GSK by 127.9% during the 1st quarter. Richardson Financial Services Inc. now owns 841 shares of the pharmaceutical company's stock valued at $33,000 after purchasing an additional 472 shares in the last quarter. Olde Wealth Management LLC bought a new position in shares of GSK during the 1st quarter valued at about $36,000. Finally, Cary Street Partners Investment Advisory LLC boosted its position in shares of GSK by 525.9% during the 1st quarter. Cary Street Partners Investment Advisory LLC now owns 1,014 shares of the pharmaceutical company's stock valued at $39,000 after purchasing an additional 852 shares in the last quarter. Institutional investors own 15.74% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Wall Street Zen upgraded shares of GSK from a "hold" rating to a "buy" rating in a research report on Sunday, August 3rd. Berenberg Bank reaffirmed a "hold" rating on shares of GSK in a research note on Tuesday, June 3rd. Six research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, GSK presently has a consensus rating of "Reduce" and a consensus price target of $37.38.

GSK Stock Up 0.6%

Shares of GSK stock traded up $0.24 during trading on Friday, hitting $39.68. 3,590,956 shares of the company were exchanged, compared to its average volume of 3,177,226. The company has a debt-to-equity ratio of 1.07, a quick ratio of 0.57 and a current ratio of 0.87. The firm has a market capitalization of $80.82 billion, a price-to-earnings ratio of 18.37, a P/E/G ratio of 1.72 and a beta of 0.53. The business's 50-day simple moving average is $38.40 and its 200 day simple moving average is $38.24. GSK PLC Sponsored ADR has a twelve month low of $31.72 and a twelve month high of $44.26.

GSK (NYSE:GSK - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 EPS for the quarter, topping the consensus estimate of $1.12 by $0.11. The business had revenue of $10.64 billion during the quarter, compared to analysts' expectations of $7.92 billion. GSK had a net margin of 10.81% and a return on equity of 49.22%. The firm's quarterly revenue was up 1.3% compared to the same quarter last year. During the same period last year, the company posted $0.43 earnings per share. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. As a group, analysts forecast that GSK PLC Sponsored ADR will post 4.14 EPS for the current fiscal year.

GSK Cuts Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 9th. Stockholders of record on Friday, August 15th will be given a $0.4206 dividend. The ex-dividend date of this dividend is Friday, August 15th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 4.2%. GSK's dividend payout ratio (DPR) is currently 77.78%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.